摘要
中国早在1982年就建立了"基本药物制度",然而,由于种种原因,这一制度没有发挥其应有的功能。重建国家基本药物制度,已经成为新医改的一项重要工作。制度重建能否成功,关键在于引入"善治"的两大原则,其一是增进利益相关者广泛的参与性,其二是提高制度的公开透明性。确保基本药物遴选程序的中立性、非个人性和透明性,让所有制药企业以观察员的身份在此过程中扮演监督者的角色,是这一制度走向"善治"的另一个关键。
It was early in 1982 that China established its essential medicines system. Nevertheless, due to many factors, the system has failed to perform its functioning. Restructuring the national essential medicines system has been incorporated into the newly released official proposal for new healthcare reforms in China. It is crucial for a successful restructuring to introduce two principles of ＂good governance＂ in public management, namely （ 1 ） wide participation of stakeholders, and （2） high - degree transparency of institutional arrangements. Another key step moving towards good governance is to ensure neutrality, impersonality, and transparency in selection of essential medicines, in which all pharmaceutical companies play a role of monitors by serving as observers.
出处
《中国行政管理》
CSSCI
北大核心
2009年第11期48-52,共5页
Chinese Public Administration
关键词
基本药物
善治
公开透明性
基本医疗保障体系
essential medicines, good governance, transparency, basic healthcare security system
